litlas
Log inCreate account

Bartomeu Massutí

Active 1999–2025

Also published as
Bartomeu Massuti
98
Papers
19,502
Citations
57
h-index
88
i10-index

Citations

Citations per year for Bartomeu Massutí1971: 4 citations1993: 2 citations1999: 2 citations2000: 12 citations2001: 9 citations2002: 19 citations2003: 17 citations2004: 17 citations2005: 15 citations2006: 39 citations2007: 53 citations2008: 58 citations2009: 58 citations2010: 92 citations2011: 133 citations2012: 125 citations2013: 213 citations2014: 172 citations2015: 215 citations2016: 205 citations2017: 190 citations2018: 193 citations2019: 549 citations2020: 540 citations2021: 617 citations2022: 506 citations2023: 463 citations2024: 711 citations2025: 434 citations2026: 9 citations1972–1992: no citations, so these years are not shown1994–1998: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,795 citing papers, 21.6% of this breakdownChina: 1,231 citing papers, 14.8% of this breakdownItaly: 503 citing papers, 6% of this breakdownSpain: 477 citing papers, 5.7% of this breakdownUnited Kingdom: 408 citing papers, 4.9% of this breakdownJapan: 389 citing papers, 4.7% of this breakdownFrance: 360 citing papers, 4.3% of this breakdownGermany: 323 citing papers, 3.9% of this breakdownSouth Korea: 240 citing papers, 2.9% of this breakdownNetherlands: 236 citing papers, 2.8% of this breakdownCanada: 225 citing papers, 2.7% of this breakdownSwitzerland: 195 citing papers, 2.3% of this breakdown
0%21.6%Other 23.4%

Institutions

Fields

  • Medicine81.3%
  • Biochemistry, Genetics and Molecular Biology13.6%
  • Immunology and Microbiology2.5%
  • Engineering0.6%
  • Computer Science0.3%
  • Chemistry0.3%
  • Other1.4%

Topics

  • Lung Cancer Treatments and Mutations17.7%
  • Cancer Immunotherapy and Biomarkers8.1%
  • Lung Cancer Diagnosis and Treatment7.8%
  • Lung Cancer Research Studies7.6%
  • Cancer Genomics and Diagnostics5%
  • Colorectal Cancer Treatments and Studies4%
  • Other49.8%

Coauthors

All papers

Open in search
  1. Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer

    Authors: Mariano Provencio, Ernest Nadal, J.L. González-Larriba, Alex Martínez‐Martí, Reyes Bernabé, Joaquim Bosch‐Barrera, Joaquín Casal‐Rubio, Virginia Calvo, Amelia Insa, Santiago Ponce, Noemı́ Reguart, Javier de Castro, Joaquín Mosquera, Manuel Cobo, Andrés Aguilar, Guillermo López-Vivanco, Carlos Camps, Rafael López Castro, Teresa Morán, I. Barneto, Delvys Rodríguez‐Abreu, Roberto Serna‐Blasco, Raquel Benítez, Carlos Aguado, Ramón Palmero, Florentino Hernándo, Javier Martín-López, Alberto Cruz‐Bermúdez, Bartomeu Massutí, Atocha Romero - New England Journal of Medicine 2023 cited by 450

  2. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

    Authors: Rafael Rosell, Enric Carcereny, Radj Gervais, A. Vergnenègre, Bartomeu Massutí, Enriqueta Felip, Ramón Palmero, Ramón García-Gómez, Cinta Pallarés, José Miguel Sánchez, Rut Porta, Manuel Cobo, Pilar Garrido, Flavia Longo, Teresa Morán, Amelia Insa, Filippo de Marinis, R. Corre, Isabel Bover, Alfonso Illiano, Éric Dansin, Javier de Castro, Michèle Milella, Noemı́ Reguart, Giuseppe Altavilla, Ulpiano Jiménez, Mariano Provencio, Miguel Ángel Moreno, Josefa Terrasa, José Muñoz-Langa, Javier Valdivia, Dolores Isla, Manuel Dómine, Olivier Molinier, Julien Mazières, Nathalie Baize, Rosario García‐Campelo, G. Robinet, Delvys Rodríguez‐Abreu, Guillermo López-Vivanco, Vittorio Gebbia, Lioba Ferrera-Delgado, P. Bombaron, Reyes Bernabé, Alessandra Bearz, Á. Artal, Enrico Cortesi, Christian Rolfo, María Sanchez-Ronco, Ana Drozdowskyj, Cristina Queralt, Itziar de Aguirre, José Luis Ramírez, José Javier Sánchez, Miguel Ángel Molina‐Vila, Miquel Tarón, Luis Paz‐Ares - The Lancet Oncology 2012 cited by 5,530

  3. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study

    Authors: Byoung Chul Cho, Delvys Rodríguez‐Abreu, Maen Hussein, Manuel Cobo, A. Patel, Nevena Sečen, Ki Hyeong Lee, Bartomeu Massutí, Sandrine Hiret, James Chih Hsin Yang, Fabrice Barlési, Dae Ho Lee, Luis Paz Ares, Robert W. Hsieh, Namrata S. Patil, Patrick J. Twomey, Xiaoying Yang, Raymond D. Meng, Melissa L. Johnson - The Lancet Oncology 2022 cited by 424

  4. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

    Authors: Mariano Provencio, Ernest Nadal, Amelia Insa, María Rosario García-Campelo, Joaquín Casal‐Rubio, Manuel Dómine, Margarita Majem, Delvys Rodríguez‐Abreu, Alex Martínez‐Martí, Javier de Castro, Manuel Cobo, Guillermo López-Vivanco, E. del Barco, Reyes Bernabé Caro, Núria Viñolas, Isidoro Barneto Aranda, Santiago Viteri, Eva Pereira, Ana Royuela, Marta Casarrubios, Clara Salas, Edwin R. Parra, Ignacio I. Wistuba, Virginia Calvo, Raquel Laza‐Briviesca, Atocha Romero, Bartomeu Massutí, Alberto Cruz‐Bermúdez - The Lancet Oncology 2020 cited by 828

  5. Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)

    Authors: Mariano Provencio, Roberto Serna‐Blasco, Ernest Nadal, Amelia Insa, M.R. García-Campelo, J. Casal Rubio, Manuel Dómine, Margarita Majem, Delvys Rodríguez‐Abreu, Alex Martínez‐Martí, Javier de Castro, Manuel Cobo, Guillermo López-Vivanco, E. del Barco, Reyes Bernabé Caro, Núria Viñolas, Isidoro Barneto Aranda, Santiago Viteri, Eva Pereira, Ana Royuela, Virginia Calvo, Javier Martín-López, Francisco Garcia‐García, Marta Casarrubios, Fernando Franco, Estela Sánchez‐Herrero, Bartomeu Massutí, Alberto Cruz‐Bermúdez, Atocha Romero - Journal of Clinical Oncology 2022 cited by 335

  6. Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

    Authors: Rafael Rosell, Teresa Morán, Cristina Queralt, Rut Porta, Felipe Cardenal, Carlos Camps, Margarita Majem, Guillermo López-Vivanco, Dolores Isla, Mariano Provencio, Amelia Insa, Bartomeu Massutí, J.L. González-Larriba, Luis Paz‐Ares, Isabel Bover, Rosario García‐Campelo, Miguel Ángel Moreno, Sílvia Catot, Christian Rolfo, Noemı́ Reguart, Ramón Palmero, José Miguel Sánchez, Roman Bastus, Clara Mayo, Jordi Bertran-Alamillo, Miguel Ángel Molina‐Vila, José Javier Sánchez, Miquel Tarón - New England Journal of Medicine 2009 cited by 2,377

  7. Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study

    Authors: Natasha B. Leighl, Hiroaki Akamatsu, Sun Min Lim, Ying Cheng, Anna Minchom, Melina E. Marmarelis, Rachel E. Sanborn, James Chih‐Hsin Yang, Baogang Liu, Thomas John, Bartomeu Massutí, Alexander I. Spira, Se‐Hoon Lee, Jialei Wang, Juan Li, Caigang Liu, Silvia Novello, Masashi Kondo, Motohiro Tamiya, Ernesto Korbenfeld, Mor Moskovitz, Ji‐Youn Han, Mariam P. Alexander, Rohit Joshi, Enriqueta Felip, Pei Jye Voon, Pongwut Danchaivijitr, Ping‐Chih Hsu, Felipe José Silva Melo Cruz, Thomas Wehler, Laurent Greillier, Encarnação Teixeira, Danny Nguyen, Joshua K. Sabari, Angel Qin, Dariusz M. Kowalski, Mehmet Alı Nahıt Şendur, John Xie, Debopriya Ghosh, Ali Alhadab, Nahor Haddish‐Berhane, Pamela L. Clemens, Patricia Lorenzini, Remy B. Verheijen, Mohamed Gamil, Joshua Bauml, Mahadi Baig, Antonio Passaro, for the PALOMA-3 Investigators, Hiroaki Akamatsu, Mariam P. Alexander, Annalen Bleckmann, Federico Cappuzzo, Ying Cheng, Byoung Chul Cho, Timuçin Çil, Alexis B. Cortot, Pongwut Danchaivijitr, Till‐Oliver Emde, Dilek Erdem, Enriqueta Felip, F. Estevinho, Maria Lurdes Ferreira, Flavio Ferreira da Silva, Maria Campelo, Laurent Greillier, Alastair Greystoke, Ji‐Youn Han, Ping‐Chih Hsu, Jen‐Yu Hung, Mei Ji, Thomas John, Rohit Joshi, Young‐Chul Kim, Masashi Kondo, Ernesto Korbenfeld, Dariusz M. Kowalski, Se‐Hoon Lee, Natasha B. Leighl, Juan Li, Sheng-Hao Lin, Baogang Liu, Caigang Liu, John Seng-Hooi Low, Melina E. Marmarelis, Bartomeu Massutí, Anna R. Minchom, Sara Moore, Mor Moskovitz, Adnan Nagrial, Danny Nguyen, Silvia Novello, Y. Ohe, Mustafa Özgüroğlu, Özgür Özyılkan, Antonio Passaro, Nir Peled, Naiyarat Prasongsook, Angel Qin, Elisa F. Ramos and 22 more - Journal of Clinical Oncology 2024 cited by 114

  8. Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)

    Authors: Ernest Nadal, Delvys Rodríguez‐Abreu, Marta Simó, Bartomeu Massutí, Óscar Juan, G. Huidobro, Rafael López Castro, Javier de Castro, Anna Estival, Joaquín Mosquera, Ivana Sullivan, Enriqueta Felip, Ana Blasco, M. Guirado, Eva Pereira, Noelia Vilariño, Valentín Navarro, Jordi Bruna - Journal of Clinical Oncology 2023 cited by 106

  9. Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non–Small-Cell Lung Cancer

    Authors: Enriqueta Felip, Rafael Rosell, J Maestre, José Manuel Rodríguez-Paniagua, Teresa Morán, Julio Astudillo, Guillermo Alonso, José Manuel Borro, J.L. González-Larriba, Antonio Torres, Carlos Camps, R. Guijarro, Dolores Isla, Rafael Aguiló, Vicente Alberola, José Padilla, Abel Sánchez‐Palencia, José Javier Sánchez, Eduardo Hermosilla, Bartomeu Massutí - Journal of Clinical Oncology 2010 cited by 430

  10. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

    Authors: Ross A. Soo, Ji‐Youn Han, Urania Dafni, Byoung Chul Cho, Chong Ming Yeo, Ernest Nadal, Enric Carcereny, J. de Castro, María Ángeles Sala, Reyes Bernabé, Linda Coate, M. Provencio Pulla, Rosario García Campelo, Sinéad Cuffe, Sayed M.S. Hashemi, Martin Früh, Bartomeu Massutí, José García-Sánchez, Manuel Dómine, Margarita Majem, J.M. Sánchez-Torres, Christian Britschgi, Miklos Pless, Georgia Dimopoulou, Heidi Roschitzki‐Voser, Barbara Ruepp, Rafael Rosell, Rolf A. Stahel, Solange Peters, Rolf A. Stahel, Solange Peters, Ross A. Soo, Ji‐Youn Han, Martin Früh, Mariano Provencio, Linda Coate, Urania Dafni, Anita Hiltbrunner, Barbara Ruepp, Heidi Roschitzki‐Voser, Anita Hiltbrunner, Adriana Gasca-Ruchti, Nino Giacomelli, Rosita Kammler, Nesa Marti, Lionel Nobs, Mariana Pardo-Contreras, Rita Pfister, Anne‐Christine Piguet, Sabrina Ribeli-Hofmann, Virginia Rodriguez Martinez, Heidi Roschitzki‐Voser, Susanne Roux, Barbara Ruepp, Magdalena Sánchez-Hohl, Mirjam Schneider, Robin Schweri, Sandra Troesch, Isabel Zigomo, Urania Dafni, Zoi Tsourti, Panagiota Zygoura, Marie Kassapian, Katerina Vervita, Georgia Dimopoulou, Charitini Andriakopoulou, Maria Fernandez, Eva Pereira, Carolina Simona, Lisa Tucker, Jillian Burnes, Aisling Barrett, Meghan McGrillen, Catherine Berset, Christine Biaggi, M. Reist, Priska Rentsch, Linda Coate, Sinéad Cuffe, Sayed M.S. Hashemi, Ernest Nadal, Enric Carcereny, Javier de Castro, María Ángeles Sala, Bernabé Reyes, Mariano Provencio Pulla, Rosario García Campelo, Bartomeu Massutí, José López García, Manuel Dómine, Margarita Majem, José Miguel Sánchez, Martin Früh, Christian Britschgi, Miklos Pless, Solange Peters, Ross A. Soo, Chong Ming Yeo, Ji‐Youn Han, Byoung Chul Cho - Annals of Oncology 2021 cited by 116

  11. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial

    Authors: Carlos Fernández-Martos, Xabier García‐Albéniz, Carles Pericay, Joan Maurel, Jorge Aparicio, Clara Montagut, María José Safont, Antonieta Salud, Ruth Vera, Bartomeu Massutí, P. Escudero, Vicente Alonso, C. Bosch, M. Martín, Bruce D. Minsky - Annals of Oncology 2015 cited by 357

  12. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy

    Authors: Marta Casarrubios, Mariano Provencio, Ernest Nadal, Amelia Insa, Rosario García-Campelo, Martín Lázaro-Quintela, Manuel Dómine, Margarita Majem, Delvys Rodríguez‐Abreu, Alex Martínez‐Martí, Javier de Castro, Manuel Cobo, Guillermo López-Vivanco, E. del Barco, Reyes Bernabé, Núria Viñolas, Isidoro Barneto Aranda, Bartomeu Massutí, Belén Sierra‐Rodero, Cristina Martínez-Toledo, Ismael Fernández‐Miranda, Roberto Serna‐Blasco, Atocha Romero, Virginia Calvo, Alberto Cruz‐Bermúdez - Journal for ImmunoTherapy of Cancer 2022 cited by 62

  13. Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial

    Authors: Mariano Provencio, Ernest Nadal, Amelia Insa, Rosario García Campelo, J. Casal, Manuel Dómine, Bartomeu Massutí, Margarita Majem, Delvys Rodríguez‐Abreu, Alex Martínez‐Martí, Javier de Castro, David Gómez de Antonio, Iván Macı́a, Santiago J. A. Figueroa, Luís Fernández Vago, Virginia Calvo, Ramón Palmero, Belén Sierra‐Rodero, Cristina Martínez-Toledo, Marta Molina-Alejandre, Roberto Serna‐Blasco, Atocha Romero, Alberto Cruz‐Bermúdez - The Lancet Oncology 2024 cited by 69

  14. Phase II, Randomized Study of Concomitant Chemoradiotherapy Followed by Surgery and Adjuvant Capecitabine Plus Oxaliplatin (CAPOX) Compared With Induction CAPOX Followed by Concomitant Chemoradiotherapy and Surgery in Magnetic Resonance Imaging–Defined, Locally Advanced Rectal Cancer: Grupo Cáncer de Recto 3 Study

    Authors: Carlos Fernández-Martos, Carles Pericay, Jorge Aparicio, Antonieta Salud, M. J. Safont, Bartomeu Massutí, Ruth Vera, P. Escudero, Joan Maurel, Eugenio Marcuello, J. Mengual, E. Saigí, Rafael Estevan, Moises Mira, Sonia Polo, Ana Lluch Hernández, Manuel Gallén, Fernando Arias, Javier Serra, Vicente Alonso - Journal of Clinical Oncology 2010 cited by 434

  15. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial

    Authors: Sebastian Michels, Bartomeu Massutí, Hans‐Ulrich Schildhaus, Jeremy Franklin, Martin Sebastian, Enriqueta Felip, Christian Grohé, Delvys Rodríguez‐Abreu, Diana S.Y. Abdulla, Helge Bischoff, Christian Brandts, Enric Carcereny, J. Corral, Anne‐Marie C. Dingemans, Eva Pereira, Jana Fassunke, Rieke Fischer, Masyar Gardizi, Lukas C. Heukamp, Amelia Insa, Anna Kron, Roopika Menon, Thors ten Persigehl, Martin Reck, Richard Riedel, Sacha I. Rothschild, Andreas H. Scheel, Matthias Scheffler, Petra Schmalz, Egbert F. Smit, Meike Limburg, Mariano Provencio, Niki Karachaliou, Sabine Merkelbach‐Bruse, Martin Hellmich, Lucia Nogová, Reinhard Büttner, Rafael Rosell, Jürgen Wolf - Journal of Thoracic Oncology 2019 cited by 131

  16. Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).

    Authors: Delvys Rodríguez‐Abreu, Melissa L. Johnson, Maen Hussein, Manuel Cobo, A. Patel, Nevena Sečen, Ki Hyeong Lee, Bartomeu Massutí, Sandrine Hiret, James C. Yang, Fabrice Barlési, Dae Ho Lee, Luis Paz‐Ares, Robert W. Hsieh, Karen B. Miller, Namrata S. Patil, Patrick Twomey, Amy V. Kapp, Raymond D. Meng, Byoung Chul Cho - Journal of Clinical Oncology 2020 cited by 242

  17. Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation Burden

    Authors: Mariano Provencio, Ana Laura Ortega Granados, Juan Coves-Sarto, Virginia Calvo, Raquel Marsé-Fabregat, Manuel Dómine, M. Guirado, Enric Carcereny, Natalia Fernández, Ruth Álvarez, Remei Blanco, Luis León‐Mateos, J.M. Sánchez-Torres, Ivana Sullivan, Manuel Cobo, Alfredo Sánchez-Hernández, Bartomeu Massutí, Belén Sierra‐Rodero, Cristina Martínez-Toledo, Roberto Serna‐Blasco, Atocha Romero, Alberto Cruz‐Bermúdez - JAMA Oncology 2022 cited by 50

  18. Lung cancer symptoms at diagnosis: results of a nationwide registry study

    Authors: Alberto Ruano‐Raviña, Mariano Provencio, Virginia Calvo de Juan, Enric Carcereny, Teresa Morán, Delvys Rodríguez‐Abreu, Rafael López Castro, Eugenio Cuadrado Albite, M. Guirado, Lucía Gómez González, Bartomeu Massutí, Ana Laura Ortega Granados, Ana Blasco, Manuel Cobo, Rosario García‐Campelo, Joaquim Bosch‐Barrera, José Trigo, Óscar Juan, Carlos Aguado de la Rosa, Manuel Dómine, María Sala, Juana Oramás, Joaquín Casal‐Rubio, S. Cerezo - ESMO Open 2020 cited by 78

  19. Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection

    Authors: Maria Gonzalez-Cao, Teresa Morán, Judith Dalmau, Javier Garcia-Corbacho, Jillian W. P. Bracht, Reyes Bernabe, Oscar Juan, Javier de Castro, Remei Blanco, Ana Drozdowskyj, Jordi Argilaguet, Andreas Meyerhans, Julia Blanco, Julia G. Prado, Jorge Carrillo, Bonaventura Clotet, Bartomeu Massuti, Mariano Provencio, Miguel A. Molina-Vila, Clara Mayo de las Casa, Monica Garzon, Peng Cao, Chung-Ying Huang, Javier Martinez-Picado, Rafael Rosell - JAMA Oncology 2020 cited by 106

  20. Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial

    Authors: Raquel Laza‐Briviesca, Alberto Cruz‐Bermúdez, Ernest Nadal, Amelia Insa, Rosario García-Campelo, G. Huidobro, Manuel Dómine, Margarita Majem, Delvys Rodríguez‐Abreu, Alex Martínez‐Martí, Javier de Castro, Manuel Cobo, Guillermo López-Vivanco, E. del Barco, Reyes Bernabé, Núria Viñolas, Isidoro Barneto Aranda, Santiago Viteri, Bartomeu Massutí, Marta Casarrubios, Belén Sierra‐Rodero, Carlos Tarín, Aránzazu García‐Grande, Cara Haymaker, Ignacio I. Wistuba, Atocha Romero, Fernando Franco, Mariano Provencio - Clinical and Translational Medicine 2021 cited by 56

  21. Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung Cancer

    Authors: Miguel Ángel Molina‐Vila, Jordi Bertrán-Alamillo, Amaya Gascó, Clara Mayo‐de‐las‐Casas, María Sánchez-Ronco, Laia Pujantell-Pastor, Laura Bonanno, Adolfo Favaretto, Andrés F. Cardona, A. Vergnenègre, Margarita Majem, Bartomeu Massutí, Teresa Morán, Enric Carcereny, Santiago Viteri, Rafael Rosell - Clinical Cancer Research 2014 cited by 198

  22. Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy

    Authors: Marta Casarrubios, Alberto Cruz‐Bermúdez, Ernest Nadal, Amelia Insa, María del Rosario García Campelo, Martín Lázaro-Quintela, Manuel Dómine, Margarita Majem, Delvys Rodríguez‐Abreu, Alex Martínez‐Martí, Javier de Castro, Manuel Cobo, Guillermo López-Vivanco, E. del Barco, Reyes Bernabé Caro, Núria Viñolas, Isidoro Barneto Aranda, Santiago Viteri, Bartomeu Massutí, Miguel Barquín, Raquel Laza‐Briviesca, Belén Sierra‐Rodero, Edwin R. Parra, Beatriz Sánchez‐Espiridión, Pedro Rocha, Humam Kadara, Ignacio I. Wistuba, Atocha Romero, Virginia Calvo, Mariano Provencio - Clinical Cancer Research 2021 cited by 67

  23. Machine Learning–Assisted Recurrence Prediction for Patients With Early-Stage Non–Small-Cell Lung Cancer

    Authors: Adrianna Janik, María Torrente, Luca Costabello, Virginia Calvo, Brian H. Walsh, Carlos Camps, Sameh K. Mohamed, Ana Laura Ortega Granados, Vít Nováček, Bartomeu Massutí, Pasquale Minervini, M. Rosario Garcia Campelo, E. del Barco, Joaquim Bosch‐Barrera, Ernestina Menasalvas, Mohan Timilsina, Mariano Provencio - JCO Clinical Cancer Informatics 2023 cited by 27

  24. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study

    Authors: Eric Van Cutsem, C. Boni, Josep Tabernero, Bartomeu Massutí, Gary Middleton, Faysal Dane, Peter Reichardt, Francisco Pimentel, Allen Lee Cohn, Philippe Follana, Michael Clemens, Alberto Zaniboni, Vladimir Moiseyenko, Mark Harrison, Donald Richards, Hans Prenen, Simon Pernot, Evelyne Ecstein-Fraïsse, Simon Hitier, P. Rougier - Annals of Oncology 2014 cited by 133